Search results for "Probiotic"

showing 10 items of 200 documents

Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lacto…

2019

Abdominal surgery represents a high risk for hospital-acquired infections and complication that may compromise the surgery outcome. Patients with recent abdominal surgery have an intestinal dysbiosis. There is evidence that probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®,an oral nutraceuticalcontaining a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 612 outpatients (344 males and 268 females, mean age 58 years) undergoing diges…

MaleLactobacillus delbrueckiiProbioticsDigestive surgery dysbiosis microbiota probiotic surveydysbiosisMiddle AgedGastrointestinal MicrobiomeLactobacillusPostoperative ComplicationsTreatment OutcomeAbdomenmicrobiotaHumansdigestive surgeryFemaleOriginal ArticlesurveyprobioticLactobacillus plantarumActa bio-medica : Atenei Parmensis
researchProduct

Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel prepa…

2019

Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®,an oral nutraceuticalcontaining a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 w…

MaleLactobacillus delbrueckiigut microbiotaProbioticsColonoscopyMiddle AgedLactobacillusPreoperative Carebowel preparationDysbiosisHumansFemaleOriginal Articlesurveybowel preparation gut microbiota colonoscopy probiotics surveyLactobacillus plantarumActa bio-medica : Atenei Parmensis
researchProduct

Routine Probiotic Use in Very Preterm Infants: Retrospective Comparison of Two Cohorts

2013

International audience; OBJECTIVE: Evidence supports the efficacy of probiotics in reducing necrotizing enterocolitis (NEC) in very low-birth-weight infants, although concerns remain with regard to their routine use. Since 2008 in our neonatal intensive care unit, a low dose of probiotics (unique strain) is administered as standard of care in all preterm babies born at 24 to 31 weeks' gestation. This study reports outcomes in infants receiving probiotic cohort (PC) compared with the historical cohort. DESIGN: Treatment with Lactobacillus rhamnosus Lcr35 (Lcr Restituo) (2 × 108 colony-forming units/12 h) was started early after birth and intention to treat was up to 36 weeks' gestation. The …

MalePediatricsTime FactorsNeonatal intensive care unit[ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/PediatricsEnteral administration0302 clinical medicineNeonatalOdds RatioInfant Very Low Birth Weight030212 general & internal medicineLacticaseibacillus rhamnosusStatisticsObstetrics and GynecologyGestational age3. Good healthCohortNecrotizing enterocolitisFemaleGastrointestinal Hemorrhagemedicine.medical_specialtyGestational AgeStatistics Nonparametric03 medical and health sciencesEnterocolitis NecrotizingSepsis030225 pediatricsIntensive careConfidence IntervalsmedicineHumansLactobacillus rhamnosusNonparametricRetrospective Studies[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsAnalysis of VarianceEnterocolitisbusiness.industryVery Low Birth WeightProbioticsInfant NewbornIntensive CareInfantRetrospective cohort studyOdds ratioNewbornmedicine.diseasePediatrics Perinatology and Child HealthIntensive Care NeonatalNecrotizingbusinessAmerican Journal of Perinatology
researchProduct

Fermented Milk Consumption and Common Infections in Children Attending Day-Care Centers: A Randomized Trial

2016

Supplemental Digital Content is available in the text

MalePediatricsmedicine.medical_specialtyLactobacillus caseiCultured Milk ProductsDay careCommunicable Diseaseslaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialrespiratory infectionlaw030225 pediatricsLactobacillus casei CNCM I-1518Cultured Milk ProductsmedicineAnimalsHumans030212 general & internal medicineChildbiologybusiness.industryIncidenceProbioticsIncidence (epidemiology)rhinopharyngitisOriginal Articles: NutritionGastroenterologyfood and beveragesChild Day Care Centersbiology.organism_classificationClinical trialLacticaseibacillus caseiMilkMulticenter studyCommon infectious diseasesChild PreschoolFermentationPediatrics Perinatology and Child HealthComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemalebusinessLactobacillus caseigastrointestinal infectionJournal of Pediatric Gastroenterology & Nutrition
researchProduct

Isolation, identification and characterisation of three novel probiotic strains (Lactobacillus paracaseiCNCM I-4034,Bifidobacterium breveCNCM I-4035 …

2013

The aim of the present study was to isolate, identify and characterise novel strains of lactic acid bacteria and bifidobacteria with probiotic properties from the faeces of exclusively breast-fed infants. Of the 4680 isolated colonies, 758 exhibited resistance to low pH and tolerance to high concentrations of bile salts; of these, only forty-two exhibited a strong ability to adhere to enterocytesin vitro.The identities of the isolates were confirmed by 16S ribosomal RNA (rRNA) sequencing, which permitted the grouping of the forty-two bacteria into three different strains that showed more than 99 % sequence identity withLactobacillus paracasei,Lactobacillus rhamnosusandBifidobacterium breve,…

MaleRotavirusLactobacillus paracaseived/biology.organism_classification_rank.speciesMedicine (miscellaneous)Biologymedicine.disease_causeBacterial AdhesionMicrobiologylaw.inventionFecesImmunocompromised HostMiceProbioticListeria monocytogenesLactobacillus rhamnosuslawLactobacillusAntibiosismedicineAnimalsHumansImmunity MucosalBifidobacteriumMice Inbred BALB CMicrobial ViabilityNutrition and DieteticsBifidobacterium breveLacticaseibacillus rhamnosusved/biologyProbioticsInfant Newbornfood and beveragesbiology.organism_classificationListeria monocytogenesSpecific Pathogen-Free OrganismsLactobacillusBreast FeedingEnterocytesSpainFemaleBifidobacteriumBreast feedingBritish Journal of Nutrition
researchProduct

The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

2016

Aim: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 pati…

MaleSettore MED/07 - Microbiologia E Microbiologia Clinicaved/biology.organism_classification_rank.specieslcsh:MedicineGastroenterologyInflammatory bowel diseaselaw.inventionProbioticchemistry.chemical_compound0302 clinical medicineLactobacillus acidophiluslawMesalamineBifidobacteriumSettore MED/12 - GastroenterologiabiologyLactobacillus salivariusMicrobiotaMedicine (all)Anti-Inflammatory Agents Non-Steroidalfood and beveragesMiddle AgedUlcerative colitisLactobacillus acidophilusTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleBifidobacteria; Inflammatory bowel diseases; Lactobacilli; Microbiota; Ulcerative colitis; Medicine (all); Biochemistry Genetics and Molecular Biology (all)Adultmedicine.medical_specialtyCombination therapyinflammatory bowel diseasesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesMesalazineDouble-Blind MethodBifidobacteriaInternal medicinemedicineHumansulcerative colitisAgedAnalysis of VarianceBifidobacterium bifidumUlcerative colitiBiochemistry Genetics and Molecular Biology (all)ved/biologybusiness.industryProbioticslcsh:Rbiology.organism_classificationmedicine.diseaseSettore MED/18 - Chirurgia GeneralechemistryLactobacilliLigilactobacillus salivariusColitis UlcerativeBifidobacterium bifidumbusiness
researchProduct

Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics.

2006

Abstract Objectives The larger number of bifidobacteria in the intestine of breast-fed infants has been associated with their better health compared with formula-fed infants. We assessed the safety and tolerability of an experimental formula containing 2 × 10 7 colony-forming units of Bifidobacterium longum BL999 and 4 g/L of a prebiotic mixture containing 90% galacto-oligosaccharides and 10% fructo-oligosaccharides. Methods A 7-mo prospective, randomized, reference-controlled, double-blinded trial was performed in infants who were not breast fed after the 14th day of birth. One hundred thirty-eight infants were enrolled and assigned to receive the control or experimental formula until they…

Malemedicine.medical_specialtyBifidobacterium longumEndocrinology Diabetes and Metabolismmedicine.medical_treatmentColony Count MicrobialOligosaccharidesBiologyWeight GainGastroenterologylaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansFood scienceProspective StudiesProspective cohort studyAdverse effectInfant Nutritional Physiological PhenomenaRespiratory Tract InfectionsNutrition and DieteticsPrebioticProbioticsInfant NewbornInfantbiology.organism_classificationBody HeightInfant FormulaIntestinesInfant formulaTolerabilityConsumer Product SafetyFemaleBifidobacteriummedicine.symptomWeight gainConstipationHeadNutrition (Burbank, Los Angeles County, Calif.)
researchProduct

Growth and safety evaluation of infant formulae containing oligosaccharides derived from bovine milk: a randomized, double-blind, noninferiority trial

2014

A limited number of nondigestible oligosaccharides are available for use in infant formula. This study evaluated growth and safety in infants fed formula supplemented with a mixture of bovine milk-derived oligosaccharides (BMOS). This mixture, which was generated from whey permeate, contains galactooligosaccharides and other oligosaccharides from bovine milk, such as 3′- and 6′-sialyllactose. We hypothesized that growth in infants fed BMOS-supplemented formula would be noninferior to that in infants fed standard formula. Healthy term infants ≤14 days old were randomly assigned to standard formula (control; n = 84); standard formula with BMOS (IF-BMOS; n = 99); or standard formula with BMOS …

Malemedicine.medical_specialtyPediatricsBifidobacterium longumOligosaccharidesGrowthWeight GainGastroenterologyInfant nutritionFecesChild DevelopmentLactobacillus rhamnosusDouble-Blind MethodInternal medicinemedicineAnimalsHumansPediatrics Perinatology and Child HealthGastrointestinal TransitFecesHealthy infantsbiologyAnthropometrybusiness.industryProbioticsInfant NewbornInfantbiology.organism_classificationConfidence intervalInfant FormulaMilkInfant formulaPediatrics Perinatology and Child HealthFood FortifiedVomitingCattleFemalemedicine.symptombusinessFlatulenceWeight gainBovine milk-derived oligosaccharidesResearch ArticleBMC Pediatrics
researchProduct

Fixation free femoral hernia repair with a 3D dynamic responsive implant. A case series report

2018

Abstract Background To date, no gold standard for the surgical treatment of femoral hernia exists. Pure tissue repair as well as mesh/plug implantation, open or laparoscopic, are the most performed methods. Nevertheless, all these techniques need sutures or mesh fixation. This implies the risk of damaging sensitive structures of the femoral area, along with complications related to tissue tear and postoperative discomfort consequent to poor quality mesh incorporation. The present retrospective multicenter case series highlights the results of femoral hernia repair procedures performed with a 3D dynamic responsive implant in a cohort of 32 patients during a mean follow up of 27 months. Mater…

Malemedicine.medical_specialtyPostoperative discomfortProstheses and Implantmedicine.medical_treatmentProsthesis ImplantationChronic pain030230 surgery3D dynamic prosthesiProsthesisFollow-Up StudieProsthesis ImplantationAbdominal wall03 medical and health sciencesFixation (surgical)0302 clinical medicineRetrospective StudiemedicineHumansHerniaHerniorrhaphyHernia repair complicationRetrospective StudiesSurgical repairPain Postoperativebusiness.industryHernia repair fixation freeProbiotic biologic responseProstheses and ImplantsGeneral MedicineMiddle AgedFemoral herniamedicine.diseaseHernia FemoralSurgeryTreatment Outcomemedicine.anatomical_structure030220 oncology & carcinogenesisFemaleSurgeryImplantbusinessHumanFollow-Up StudiesInternational Journal of Surgery
researchProduct

Tuning gut microbiota through a probiotic blend in gemcitabine‐treated pancreatic cancer xenografted mice

2021

Medicine (General)Transplantation HeterologousMedicine (miscellaneous)Gut floraSettore MED/08 - Anatomia PatologicaDeoxycytidineLetter to Editorlaw.inventionProbioticMiceR5-920lawPancreatic cancermedicineAnimalsbiologybusiness.industryProbioticsbiology.organism_classificationmedicine.diseaseGemcitabineGemcitabineGastrointestinal Microbiomegut microbiota gemcitabine pancreatic cancer xenografted micePancreatic NeoplasmsCancer researchMolecular Medicinebusinessmedicine.drugClinical and Translational Medicine
researchProduct